The company has market cap of $1.11 billion. The hedge fund run by Wilmot B. Harkey held 386,494 shares of the consumer services company at the end of 2016Q4, valued at $4.12 million, down from 703,471 at the end of the previous reported quarter. On July 26 the company was changed to "Market Perform" by BMO Capital which is down from the previous "Outperform" rating. De La Rue plc (LON:DLAR) has 0.00% since September 13, 2016 and is. About 430,716 shares traded or 40.07% up from the average. MA grew its stake in shares of Amgen Inc. It has underperformed by 11.43% the S&P500.
Westwood Global Investments Llc increased Tenaris (TS) stake by 1.75% reported in 2016Q4 SEC filing. Pentwater Capital Management Lp sold 121,650 shares as Aetna Inc (AET)'s stock rose 12.84%. (NASDAQ:AMGN). Murphy Pohlad Asset Mngmt invested in 0.15% or 1,378 shares. It closed at $189.44 lastly. Tenaris SA (ADR) (NYSE:TS) has risen 25.06% since September 14, 2016 and is uptrending. It has outperformed by 12.14% the S&P500. One research analyst has rated the stock with a sell rating, twelve have given a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company's stock. Therefore 43% are positive. As per Friday, November 18, the company rating was downgraded by JMP Securities. UBS upgraded the shares of AMGN in report on Monday, September 7 to "Buy" rating. The firm earned "Buy" rating on Wednesday, August 23 by Oppenheimer. The stock has "Buy" rating by Oppenheimer on Wednesday, July 12. Piper Jaffray maintained it with "Overweight" rating and $200 target in Saturday, August 29 report. Moreover, First National Bank & Trust Of Omaha has 0.23% invested in Amgen, Inc. (NASDAQ:AMGN) on Wednesday, April 5 to "Hold" rating. The firm realized a fall in short interest of -9.53% between July 31, 2017 and August 15, 2017.
Since March 21, 2017, it had 0 insider purchases, and 5 insider sales for $23.74 million activity. 3,700 Amgen, Inc. (NASDAQ:AMGN) shares with value of $569,541 were sold by BALTIMORE DAVID. Twin Tree Mgmt Ltd Partnership invested 0.06% of its portfolio in Amgen, Inc. The company recently declared a dividend for shareholders that was paid on Friday September 8th, 2017. (NASDAQ:AMGN). L And S Advisors invested 0.05% of its portfolio in Amgen, Inc. The ex-dividend date was Tuesday the 15th of August 2017.
Investors sentiment decreased to 1.15 in Q4 2016. Its down 0.10, from 1.25 in 2016Q3. It dived, as 98 investors sold AMGN shares while 488 reduced holdings. Arvest Bank Trust Division now owns 1,508 shares of the medical research company's stock worth $260,000 after purchasing an additional 13 shares during the period. Fukoku Mutual Life Insur owns 3,500 shares or 0.09% of their USA portfolio. Cohen Klingenstein Limited Liability Com invested in 0.82% or 33,020 shares. Investment Partners Ltd. OH ADV raised its position in shares of Amgen by 0.5% during the second quarter.
Several equities research analysts recently commented on AMGN shares. Natixis Asset has invested 0.15% of its portfolio in Amgen, Inc. AMGN's profit will be $2.24 billion for 15.43 P/E if the $3.07 EPS becomes a reality.
Cantab Capital Partners Llp augmented its holdings by buying 2,601 shares an increase of 35.4% from 03/31/2017 to 06/30/2017. 8,257 were reported by Waters Parkerson And Ltd Liability. Janus Henderson Group PLC now owns 3,699,351 shares of the medical research company's stock worth $637,139,000 after acquiring an additional 3,601,087 shares during the period. Research And Mgmt accumulated 0.27% or 5,314 shares. Its down 6.24% from 1.29 million shares previously. Aperio has invested 0.35% of its portfolio in Amgen, Inc.
More notable recent Amgen, Inc. (NASDAQ:AMGN). 9,435 are held by Bridgecreek Mngmt Limited Liability. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.11 by $0.16. Highland Cap Limited Company reported 39,830 shares.
Whetstone Capital Advisors Llc holds 6.47% of its portfolio in Envestnet Inc for 341,526 shares.
A total of 17 brokerages have issued a ratings update on Amgen Inc. Cypress Capital Group's holdings in Amgen were worth $1,753,000 at the end of the most recent quarter. (NASDAQ:AMGN) to report earnings on October, 26. Amgen's revenue was up 2.1% compared to the same quarter past year. In the latest earnings report the EPS was $10.98 and is projected to be $12.57 for the current year with 729,674,000 shares now outstanding. They expect $3.07 earnings per share, up 1.66% or $0.05 from last year's $3.02 per share. Therefore 50% are positive. Aetna had 45 analyst reports since July 30, 2015 according to SRatingsIntel. They set a "sector perform" rating and a $192.00 target price for the company. Cann reaffirmed a "buy" rating and set a $203.00 target price (up from $189.00) on shares of Amgen in a research report on Wednesday, July 26th. The stock has "Hold" rating by Standpoint Research on Friday, October 16. (NYSE:RSO) has "Hold" rating given on Monday, August 10 by Deutsche Bank. The firm earned "Hold" rating on Wednesday, June 7 by Bernstein. (NASDAQ:AMGN) rating on Monday, September 7. The stock of NetEase Inc (ADR) (NASDAQ:NTES) has "Hold" rating given on Thursday, September 29 by Jefferies. The stock has "Neutral" rating by Credit Suisse on Tuesday, December 20.